Xencor, Inc. develops engineered antibody therapeutics for cancer and autoimmune diseases using its XmAb technology platform and related antibody-engineering formats. News about XNCR commonly covers clinical and preclinical updates for XmAb drug candidates, including TL1A programs such as XmAb942 and XmAb412, T-cell engaging bispecific antibodies such as XmAb819 and XmAb541, and presentations of data at medical meetings.
Recurring company updates also include quarterly financial results, research-and-development priorities, collaboration and licensing activity, intellectual-property developments tied to Xtend Fc domain technology, and royalty matters involving partner-marketed medicines such as Ultomiris.
Xencor, Inc. (NASDAQ:XNCR) announced initial data from its ongoing Phase 1 study of tidutamab (XmAb®18087), a bispecific antibody targeting neuroendocrine tumors (NETs). Presented at the NANETS 2020 symposium, the preliminary results indicate that tidutamab was well-tolerated, showing dose-dependent T-cell proliferation. The study involved 27 patients with various NETs, achieving a disease control rate of 43%. Xencor plans further studies in Merkel cell carcinoma and small cell lung cancer, emphasizing tidutamab's promising safety profile and potential efficacy in solid tumors.